Research Paper Volume 13, Issue 16 pp 20661—20683
METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas
Figure 4. Prognostic value of METTL21B for patients with LGG in TCGA. The effect of METTL21B expression on overall survival (A) and progression-free survival (C) of patients; The ROC curve for OS (B) and PFS (D).